M. Gabriela Cabanilla, PharmD, PhC is an assistant professor at the University of New Mexico College of Pharmacy and an inpatient infectious diseases pharmacist clinician at the University of New Mexico Hospital in Albuquerque, NM. Cabanilla's clinical interests include immunocompromised infectious diseases and optimizing antimicrobial dosing in the critically ill, particularly in ECMO. ORCID ID: 0000-0001-5402-0240
The expanding Gram-negative antibiotic pipeline offers important new treatment options; however, FDA approval alone does not define a drug’s place in therapy. Clinicians must weigh the clinical problems each agent solves, the strength of the evidence behind it, and what remains unknown before incorporating these therapies into routine practice.
In the latest article from SIDP, here is a look at the use of various intravenous (IV) antimicrobial therapies to address infections in these patients.
